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Abstract 
We show that intensification of treatment with maraviroc in patients chronically infected with HIV-1 
receiving successful long-term ART was not associated with improvements in HIV related morbidity, 
HIV reservoir, microbial translocation, immune activation or immune exhaustion in either gut or 
peripheral blood.   The measurement of reservoir in both gut and blood longitudinally contributes to 
a paucity of data in the area.  
Background 
Despite the huge success of antiretroviral therapy (ART), increased morbidity compared with HIV 
uninfected individuals continues [1], particularly in those with a blunted CD4 response to ART [2]. A 
cure for HIV remains elusive and this is in part due to an inaccessible long-lived pool of latently 
infected cell; the viral reservoir, which is focused in the gut-associated lymphoid tissue [3].   
 
Intensification of ART in individuals with suppressed plasma viremia has not consistently reduced 
viral reservoir or improved immune function [4,5]. The C-C chemokine receptor type 5 (CCR5) entry 
inhibitor, maraviroc, is an attractive option as CCR5 receptors are most numerous in the gut and the 
drug penetrates tissue well [6]. Studies suggest a possible role in increasing CD4 count [7,8] and 
reducing immune activation  [5,9]. The gut has been less investigated [4], with no consensus on 
microbial translocation [5,11] or immune activation [11]]. 
 
We investigated the effect of maraviroc intensification on gut immune function and viral reservoir.  
 
Methods 
Study Design and recruitment 
A prospective study whereby 10 individuals with chronic HIV infection with sustained virological 
suppression on ARV for >12 months and a CD4+ T cell count below 500 cells/mm,3 were intensified 
with a 24-week course of standard dose maraviroc. Blood samples were collected at week 0, 4, 12 
and 24. At baseline and week 24, individuals underwent flexible sigmoidoscopy, in which eight-ten 
rectal biopsies were taken and fixed overnight in 10% normal buffered formalin at 4°C. 
 
Laboratory Tests  
Bacterial translocation 
Plasma bacterial 16s DNA was quantified by real time PCR [11]. Plasma sCD14 was quantified using 
the Quantikine Human sCD14 Immunoassay (R&D Systems, Minnesota, USA), according to 
manufacturer’s instructions. All samples were run in duplicate. 
 
HIV Reservoir and residual Viraemia 
Low copy viral load was measured with an internally controlled ultrasensitive quantitative real-time 
RT-PCR able to detect 3 copies/ml. Purified peripheral blood CD4 T cells were analyzed by qPCR for 
HIV-1 DNA (Total and Integrated) and cell-associated HIV-1 RNA unspliced transcripts (CA-RNA) as 
reported elsewhere [12]. 
 For preparation of the gut biopsies for HIV reservoir quantitation, a commercial kit was used (Qiagen, 
Cat. No. 56404), and the manufacturer’s protocol modified as follows to ensure maximum yield of 
DNA. Biopsy sections were removed from paraffin blocks using a scalpel and placed into 1.5ml micro 
centrifuge tubes. Samples were washed repeatedly with xylene and ethanol until the precipitate had 
disappeared, then dried at room temperature.  Biopsy sections were incubated at 37°C and DNA 
extracted using a commercial kit (QIAAMP DNA FFPE Tissue Extraction Kit, ID 56404, Qiagen (Hilden, 
Germany)). The resulting DNA was eluted into 200ųl and analysed by qPCR using the same assays for 
peripheral blood CD4 cells detailed above. 
 
Immune activation and lymphocyte subsets  
PBMC were stained with the anchor markers (CD3- VioBlue, CD4(VIT4)-VioGreen, CD8-APC) and a 
Live/Dead marker Near IR- APC-Cy7 plus either an activation panel (CD25(3G10)-PE, CD38-PE-Vio770, 
CD69-FITC, Anti-HLA-DR-PerCP) or an exhaustion panel (TIGIT-PE, TIM-3-FITC, LAG-3-PerCPeF710, 
PD1-PE-Cy7). Cells were run on a MACSQuant and analysed with FlowJo software v10 (Miltenyi 
Biotec).  
 
 Immunohistochemistry  
Rectal biopsy sections were stained for CD4 (goat polyclonal, Novus Biologicals) and CD8 antibodies 
(rabbit polyclonal, Abcam). Images were analysed in ImageJ and the distribution of cells determined 
as described by Milano et al [13]. 
 
Statistics 
For each outcome measure, the results at baseline and week 24 were compared using the paired T-
test. Wilcoxon rank test was used to assess the impact of tropism on each parameter. 
 
Results: 
Patient characteristics 
The median age was 46 years. All patients were male with subtype B virus and were receiving two 
nucleoside reverse transcriptase inhibitors (NRTI) combined with either a non-nucleoside reverse 
transcriptase inhibitor (n=5) or protease inhibitor (n=5).  The mean CD4 T cell count was 321 cells/uL 
(SD 112), CD4:CD8 0.51 (SD 0.27) and nadir CD4 117 cells/mL (SD 135).   All patients maintained an 
HIV viral load <50 copies/ml throughout the study. Individual plots of viral reservoir, microbial 
translocation and immune activation are shown in table 1 and mean changes in parameters between 
week 0 and 24 are shown in figure 1. 
 
Baseline to week 24:  
- Clinical outcome / T-cell subsets composition in blood and gut 
Between baseline and week 24 in the blood, there was a non-significant increase of 48.22 CD4 T 
cells/mL (p=0.275) and 39.23 CD8 T cells/mL (p=0.672) whilst CD4:CD8 did not change. This was 
accompanied by a non-significant reduction in gut CD4 (-0.80 p= 0.087) and gut CD8 T cells (-5.59 
p=0.052). Changes in blood CD4 and CD8 lymphocytes did not correlate with changes in these cells in 
the gut. 
 
- Bacterial translocation 
Between baseline and week 24 there was no significant change in 16s DNA copies (-0.60;p=0.797) or 
sCD14a (+59.35  p=0.637). 
 
- HIV reservoir 
Neither HIV RNA, HIV DNA (blood or gut) or cellular HIV RNA changed significantly between baseline 
and week 24 or between baseline and week 12.  At baseline gut HIV DNA levels (mean 101806 
copies/million cells) were significantly higher than blood (3669 copies/million CD4 T cells) (p=0.017).   
 
- T-cell activation and exhaustion 
The level of activation of CD4 + T cells and CD8+ T cells showed non- significant increases from 
baseline to week 24 in 6 parameters (including CD8+CD38+HLADR;p=0.677) with only %CD8+HLADR 
(+0.61 p=0.048) increasing significantly. These findings were the same when analysed from baseline 
to week 12 with only %CD8+ HLADR+ showing a significant change (+0.47; p= 0.001).  
Eight out of 10 immune exhaustion markers increased from baseline to week 24 but only CD8% Tigit 
reached significance (+6.07; p=0.006). This was supported by analysis of week 0 to week 12 (% CD8 
Tigit (mean increase +5.82; p=0.004). 
 
Tropism: 
Six out 10 individuals had R5 virus. Tropism (R5 v X4 or X4/R5) did not correlate with changes in 
reservoir, immune activation, immune exhaustion or microbial translocation (all P values >0.05).  
 
Discussion: 
In this pilot study, intensification of treatment with maraviroc in patients chronically infected with 
HIV-1 receiving successful long-term ART with a blunted CD4 immune response was not associated 
with any overall improvements in surrogate markers of HIV related morbidity (CD4 T cell count or 
CD4:CD8 ratio), microbial translocation, immune activation or immune exhaustion in either gut or 
peripheral blood. The isolated significant results in the absence of a broad class-wide effect on T cell 
exhaustion or activation are potentially interesting but should not be over-interpreted. Furthermore, 
reservoir did not decline longitudinally either gut or blood.  The large gut HIV reservoir supports 
interventions targeting this compartment; however, the large intra-individual variation means that 
sample sizes may need to be large.   The lack of impact of tropism on the effect of maraviroc on 
immunological function or reservoir size is novel but limited due to small sample size.   
 
Overall, the study shows no role for maraviroc intensification to improve clinical orimmunological 
outcomes or to provide complete viral inhibition. The null effect may also reflect that these 
individuals had more resistant immune dysfunction than intensification with antiretroviral therapy 
could repair or the short duration of follow up. The study is limited by the small sample size and lack 
of control group but the detailed analysis particularly of the gut further diminishes the investigation 
of maraviroc as an agent of intensification.  
 
Acknowledgment: we acknowledge support from the Infectious diseases biobank nurse funded by 
Guys and St Thomas’ NHS Trust and NIHR.
References 
1. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 
2010 Jul 3;376(9734):49-62 
2. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, 
Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M. CD4 T-lymphocyte recovery 
in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 
years: the swiss HIV cohort study. Arch Intern Med. 2003;163:2187–2195. 
3. Chun TW, Fauci AS Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl 
Acad Sci U S A 1999; 96:10958–61.  
4. Ananworanich J, Chomont N, Fletcher JL, Pinyakorn S, Schuetz A, Sereti I, Rerknimitr R, 
Dewar R, Kroon E, Vandergeeten C, Trichavaroj R, Chomchey N, Chalermchai T, Michael NL, 
Kim JH, Phanuphak P, Phanuphak N. Markers of HIV reservoir size and immune activation 
after treatment in acute HIV infection with and without raltegravir and maraviroc 
intensification. J Virus Erad. 2015;1(2):116-122. Epub 2015  
5. Gutiérrez C, Díaz L, Vallejo A, et al. Intensification of antiretroviral therapy with a CCR5 
antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. PLoS 
ONE 2011;6(12):e27864 
6. Fox J, Tiraboschi J, Herrera C, Else L, Dickinson L, Back D, Khoo S, Boffitto M. 
Pharmacokinetic/pharmacodynamic investigation of single dose oral maraviroc in the 
context of HIV-1 pre exposure prophylaxis (PrEP). J Acquir Immune Defic Syndr 2016 Nov 
1;73(3):252-257 
7. Asmuth DM, Goodrich J, Cooper DA, Haubrich R, Rajicic N, Hirschel B, et al. CD4+ T-cell 
restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. 
J Acquir Immune Defic Syndr. 2010;54: 394–7.  
8. Cuzin L, Trabelsi S, Delobel P, et al. ; ANRS 145 MARIMUNO Study Group. Maraviroc 
intensification of stable antiviral therapy in HIV-1-infected patients with poor immune 
restoration: MARIMUNO-ANRS 145 study. J Acquir Immune Defic Syndr 2012;61(5):557-564.  
9. Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, et al. Effects of 
maraviroc andefavirenz on markers of immune activation and inflammation and associations 
with CD4+ cell rises in HIV-infected patients. PLoS One. 2010;5: e13188  
10. Hunt PW, Shulman NS, Hayes TL, et al. The immunologic effects of maraviroc intensification 
in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. 
Blood 2013;121(23):4635-4646. 
11. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, Landay A, Martin J, Sinclair E, 
Asher AI, Deeks SG, Douek DC, Brenchley JM. Plasma levels of bacterial DNA correlate with 
immune activation and the magnitude of immune restoration in persons with antiretroviral-
treated HIV infection.  J Infect Dis. 2009 Apr 15;199(8):1177-85. 
12. Williams J.P., Hurst J., Stohr W. HIV-1 DNA predicts disease progression and post-treatment 
virological control. eLife. 2014;3:e03821. 
13. Bologna-Molina R, Damián-Matsumura P, Molina-Frechero N. An easy cell counting method 
for immunohistochemistry that does not use an image analysis program. Histopathology 
2011 Oct;59(4):801-3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: individual values for key parameters between week 0 and week 24 
 
 
Participant CD8CD38 16sDNA HIVDNA 
A 0 24 0 24 0 24 
B 2.07 65.4 9.59 24.79 2261.3 1613.3 
C 31.4 3.77 13.73 6.84 2961.3 2330.2 
D 67.4 72.1 4.49 5.41 2961.4 747.3 
E 40 79.4 4.89 6.51 2877.3 2826.5 
F 7.96 68.5 3.65 3.38 3621.1 1645.3 
G 28.5 6.08 6.59 2.07 4141.3 4384 
H 71 55.1 4.87 3.47 4968.3 6701.6 
I 78.1 3.1 7.72 7.6 8452.1 12026.7 
J 67.7 16.7 10.61 4.21 2129.7 1968 
 
 
 
Table 2: Mean changes in parameters between week 0 and 24 
Outcome variable 
Mean (SD) 
Week 0 (visit 
2) 
N=10 
Mean (SD)  
Week 24 
(visit 5)  
N=9 
Mean 
difference  
(week 24 - 
week 0) 
N=9  
P.value  
Microbial 
translocation 
    
16s DNA copies/ul 7.95(3.7)  7.69(6.73)  -0.60  0.7972  
scd14 ng/mL 
1781.56(355.
16)  
1783.02(438.
14)  
59.35  0.6368  
     
Clinical outcome 
markers 
    
CD4 cells/ml 334.4(131.64)  
407.56(154.6
3)  
48.22  0.2751  
CD4%  24.39(8.77)  24.39(7.02)  -1.29  0.3349  
CD4:CD8 ratio  0.51(0.27)  0.54(0.21)  0  1  
     
Reservoir     
HIV DNA copies/ CD4 
T cell  
3669.41(1902
.92)  
3181.33(348
4.3)  
-343.76  0.5594  
Cell HIV RNA copies/ 
18s RNA copies 
2755.62(4400
.75)  
991.18(1130.
88)  
-1295.49  0.5279  
Low copy plasma HIV 
RNA/ml 
16.1(14.96)  38.33(38.12)  21.78  0.1424  
     
Immune Exhaustion     
% CD8 lag3  0.91(1.08)  0.44(0.22)  -0.52  0.2669  
% CD8pd1  0.27(0.23)  0.55(0.41)  0.27  0.1762  
% CD8 tigit  47.23(13.79)  52.08(16.23)  6.07  0.0059  
% CD8 tim3  0.1(0.09)  0.11(0.1)  0  0.9191  
% CD4 lag3  0.24(0.21)  0.26(0.2)  0.08  0.3693  
% CD4 pd1  1.01(1.08)  1.64(1.24)  0.98  0.0596  
% CD4 tim3  0.32(0.35)  0.26(0.2)  -0.01  0.9074  
% CD4 tigit  26.56(10.01)  25.3(10.36)  1.63  0.5215  
     
Immune activation     
% CD4CD25  1.73(0.89)  2.19(2.07)  0.58  0.4762  
% CD4CD38  0.95(0.52)  1.15(0.94)  0.37  0.2302  
% CD4CD69  1.4(1.15)  1.29(0.89)  0.21  0.3268  
% CD4 HLA DR  4.74(2.5)  5.08(3.01)  1.32  0.163  
% CD8CD38  45.67(27.47)  31.59(34.97)  -16.37  0.3669  
% CD8CD25  2.04(1.3)  1.77(1.77)  -0.63  0.3275  
% CD8CD69  5.7(4.34)  3.66(1.82)  -2.16  0.326  
% CD8 HLA DR  0.82(0.59)  1.22(0.9)  0.61  0.0482  
% CD8CD38 HLA DR  0.82(0.59)  1.23(0.84)  0.58  0.0326  
     
Gut tissue reservoir     
HIV DNA copies/ 
million cells 
101805.93(11
7858.81)  
51468.83(10
9191.98)  
-44062.84  0.4738  
     
Gut cell composition     
Total cell number 93.9(22.33)  93.59(28.52)  1.26  0.9006  
CD4 cell number 22.9(12.52)  16.41(9.98)  -8.04  0.0873  
CD8 cell  number  11.5(5.79)  6.26(4.57)  -5.59  0.0522  
Proportion of CD4 
cells 
0.25(0.16)  0.18(0.12)  -0.09  0.0644  
Proportion of CD8n 
cells 
0.12(0.05)  0.08(0.05)  -0.05  0.0898  
 
 
Figure 1: individual change in key parameters between week 0 and week 24 
 
 
